News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Invitrogen Corporation (IVGN) and CytRx Laboratories, Inc. Subsidiary RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications


11/14/2007 12:09:10 PM

CARLSBAD, Calif. & WORCESTER, Mass.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and CytRx Corporation’s (NASDAQ:CYTR) majority-owned subsidiary RXi Pharmaceuticals Corporation (RXi) today announced that they have entered into an agreement whereby RXi will exclusively license second generation RNA interference (RNAi) technology from Invitrogen for designated target genes in all human therapeutic categories.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES